Antibody to Human AXL

<strong>Antibody to Human AXL</strong>_x000D_ <strong>Catalog number:</strong> B2015519_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 25 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> ARK or UFO_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Wang W, Zhao J, Wen X, Lin CC, Li J, Huang Q, Yu Y, Lin SY, Li C. MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer Contrast Media Mol Imaging. 2017 May 14;2017:1686525._x000D_ 2: Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, Penault-Llorca F, Pasquet JM, Pèlegrin A, Robert B. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy Oncogene. 2014 Nov 20;33(47):5405-14._x000D_ 3: Nimmagadda S, Pullambhatla M, Lisok A, Hu C, Maitra A, Pomper MG. Imaging Axl expression in pancreatic and prostate cancer xenografts Biochem Biophys Res Commun. 2014 Jan 10;443(2):635-40._x000D_ 4: Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer Breast Cancer Res. 2017 May 2;19(1):54._x000D_ 5: Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy Br J Cancer. 2017 Feb 14;116(4):415-423._x000D_ 6: Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications Mol Cancer. 2019 Nov 4;18(1):153._x000D_ 7: Tanaka M, Siemann DW. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer Int J Mol Sci. 2021 Sep 15;22(18):9953._x000D_ 8: Zdżalik-Bielecka D, Poświata A, Kozik K, Jastrzębski K, Schink KO, Brewińska-Olchowik M, Piwocka K, Stenmark H, Miączyńska M. The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):e2024596118._x000D_ 9: Duan Y, Luo L, Qiao C, Li X, Wang J, Liu H, Zhou T, Shen B, Lv M, Feng J. A novel human anti-AXL monoclonal antibody attenuates tumour cell migration Scand J Immunol. 2019 Aug;90(2):e12777._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/31088471">10: Myers KV, Amend SR, Pienta KJ. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment Mol Cancer. 2019 May 14;18(1):94. </a>_x000D_ _x000D_ <strong>Products Related to Antibody to Human AXL can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>